Clinical Trials and Research News Weekly Roundup | Ivermectin Repurposing for COVID-19: The Israeli Perspective

‘Generic Drug Repurposing for COVID-19” The Israeli Perspective’:Tel Aviv University’s Spark program recently hosted a webinar titled “Generic Drug Repurposing for COVID-19: The Israeli Perspective.” In collaboration with the MedInsight Institute, presenters included Professor Alex Jadad, Faculty of Medicine and School of Public Health, University of Toronto, Canada; Moshe Rogosnitzky, Executive Director, MedInsight Research Institute from both New York and Israel; professor Yaakov Nahmias, Director for the Center of Bio engineering, the Hebrew University of Jerusalem; and Professor Eli Schwartz with Sheba Medical Center, Tel Aviv University, #Israel, who presented the “Sheba #Ivermectin Project (SIP).” Establishing a movement in Israel to consider the repurposing of generic drugs for purposes of economically and forcefully targeting #COVID-19, the drugs discussed in this presentation included Ivermectin, are potentially safe, effective and widely accessible. The organizers of this event are clear for the world to hear: “Of the 9,000 currently approved drugs that exist globally, the potential for overcoming COVID-19 certainly exists...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee